966 related articles for article (PubMed ID: 33313272)
1. Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
Zhang ZL; Zhong H; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Ann Transl Med; 2020 Nov; 8(22):1527. PubMed ID: 33313272
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for COVID-19 among healthcare workers. A protocol for a systematic review and meta-analysis.
Dzinamarira T; Mhango M; Dzobo M; Ngara B; Chitungo I; Makanda P; Atwine J; Nkambule SJ; Musuka G
PLoS One; 2021; 16(5):e0250958. PubMed ID: 33945546
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of depression during the SARS, MERS, and COVID-19 pandemics: A protocol for overview of systematic reviews.
Du L; Chen YM; Li Y; Yuan W; Wang JS
Medicine (Baltimore); 2020 Sep; 99(38):e22235. PubMed ID: 32957366
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Momattin H; Mohammed K; Zumla A; Memish ZA; Al-Tawfiq JA
Int J Infect Dis; 2013 Oct; 17(10):e792-8. PubMed ID: 23993766
[TBL] [Abstract][Full Text] [Related]
9. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
[TBL] [Abstract][Full Text] [Related]
10. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features of coronavirus disease 2019 in children: a systemic review of severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019].
He Y; Tang J; Zhang M; Wang HR; Li WX; Xiong T; Li YP; Mu DZ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Aug; 22(8):844-853. PubMed ID: 32800031
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of
Han YJ; Lee KH; Yoon S; Nam SW; Ryu S; Seong D; Kim JS; Lee JY; Yang JW; Lee J; Koyanagi A; Hong SH; Dragioti E; Radua J; Smith L; Oh H; Ghayda RA; Kronbichler A; Effenberger M; Kresse D; Denicolò S; Kang W; Jacob L; Shin H; Shin JI
Theranostics; 2021; 11(3):1207-1231. PubMed ID: 33391531
[No Abstract] [Full Text] [Related]
16. Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.
Hoang T; Anh TTT
Infect Chemother; 2020 Sep; 52(3):317-334. PubMed ID: 32869558
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Diabetes Mellitus and Its Associated Unfavorable Outcomes in Patients With Acute Respiratory Syndromes Due to Coronaviruses Infection: A Systematic Review and Meta-Analysis.
Pinedo-Torres I; Flores-Fernández M; Yovera-Aldana M; Gutierrez-Ortiz C; Zegarra-Lizana P; Intimayta-Escalante C; Moran-Mariños C; Alva-Diaz C; Pacheco-Barrios K
Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420962495. PubMed ID: 33177910
[TBL] [Abstract][Full Text] [Related]
18. Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.
Saleki K; Yaribash S; Banazadeh M; Hajihosseinlou E; Gouravani M; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2021 Sep; 906():174248. PubMed ID: 34126092
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
20. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
